4.07
-0.01(-0.25%)
Currency In USD
| Previous Close | 4.08 |
| Open | 4.03 |
| Day High | 4.12 |
| Day Low | 3.9 |
| 52-Week High | 11 |
| 52-Week Low | 2.83 |
| Volume | 835,697 |
| Average Volume | 800,346 |
| Market Cap | 51.97M |
| PE | -1.49 |
| EPS | -2.74 |
| Moving Average 50 Days | 5.16 |
| Moving Average 200 Days | 5.89 |
| Change | -0.01 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $81.4 as of August 20, 2025 at a share price of $4.07. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $603.86 as of August 20, 2025 at a share price of $4.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
GlobeNewswire Inc.
Aug 18, 2025 11:05 AM GMT
Ensures Intellectual Property Protection Until 2040LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
GlobeNewswire Inc.
Jul 24, 2025 12:00 PM GMT
OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burdenLOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company develo
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire Inc.
Jul 08, 2025 12:30 PM GMT
--Nasdaq compliance follows reverse stock split previously announced on June 17, 2025LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology com